J2353 HCPCS code: Injection, octreotide, depot form for intramuscular injection, 1 mg
J2353 is the HCPCS Level II code for injection, octreotide, depot form for intramuscular injection, 1 mg. In 2024 Medicare paid an average of $163.94 per service for J2353 across 583,588 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 60 per day on outpatient hospital claims. Medicare volume fell 18% from 2022 to 2024 (709,660 to 583,588 services). In 2024, about 2,837 clinicians billed Medicare for J2353 for 2,645 beneficiaries; Florida, California, Texas accounted for 34% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2004-01-01 |
| Last action effective | 2004-01-01 |
Who bills J2353 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 2,837 |
| Medicare beneficiaries | 2,645 |
| States with claims | 36 |
| Share of services in top 3 states (Florida, California, Texas) | 34% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2353, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 709,660 | 3,094 | $201.61 | $160.73 |
| 2023 | 664,039 | 2,946 | $199.77 | $158.96 |
| 2024 | 583,588 | 2,645 | $206.09 | $163.94 |
States with the most J2353 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 72,945 | $163.39 |
| California | 62,991 | $162.56 |
| Texas | 56,354 | $165.62 |
| Illinois | 32,816 | $163.22 |
| Virginia | 28,232 | $166.26 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 60 | Clinical: Society Comment |
| practitioner claims | 60 | Clinical: Society Comment |
Medicare policy articles for this code
- A56531: Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot) (Palmetto GBA (MAC - Part B))
Covered diagnoses (72 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| C25.4 | Malignant neoplasm of endocrine pancreas | 1 |
| C26.0 | Malignant neoplasm of intestinal tract, part unspecified | 1 |
| C37 | Malignant neoplasm of thymus | 1 |
| C7A.010 | Malignant carcinoid tumor of the duodenum | 1 |
| C7A.011 | Malignant carcinoid tumor of the jejunum | 1 |
| C7A.012 | Malignant carcinoid tumor of the ileum | 1 |
| C7A.019 | Malignant carcinoid tumor of the small intestine, unspecified portion | 1 |
| C7A.020 | Malignant carcinoid tumor of the appendix | 1 |
| C7A.021 | Malignant carcinoid tumor of the cecum | 1 |
| C7A.022 | Malignant carcinoid tumor of the ascending colon | 1 |
Showing 10 of 72. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J2353
- 2004-01-01: J2353 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2353?
J2353 is the HCPCS Level II code for injection, octreotide, depot form for intramuscular injection, 1 mg. Short descriptor: "Octreotide injection, depot".
How much does Medicare pay for J2353?
In 2024, the average Medicare payment was $163.94 per service (average allowed $206.09).
Does Medicare cover J2353?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J2353?
Medicare policy articles that cite J2353 list 72 covered ICD-10-CM diagnosis codes across 1 article. The most cited include C25.4 (Malignant neoplasm of endocrine pancreas), C26.0 (Malignant neoplasm of intestinal tract, part unspecified), C37 (Malignant neoplasm of thymus). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J2353 can be billed per day?
60 on outpatient hospital claims; 60 on practitioner claims (NCCI medically unlikely edits).
Related J23 codes
- J2300 — Injection, nalbuphine hydrochloride, per 10 mg
- J2305 — Injection, nitroglycerin, 5 mg
- J2310 — Injection, naloxone hydrochloride, per 1 mg
- J2311 — Injection, naloxone hydrochloride (zimhi), 1 mg
- J2312 — Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 — Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 — Injection, naltrexone, depot form, 1 mg
- J2320 — Injection, nandrolone decanoate, up to 50 mg
- J2323 — Injection, natalizumab, 1 mg
- J2325 — Injection, nesiritide, 0.1 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2327 — Injection, risankizumab-rzaa, intravenous, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2353
- Watch J2353 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2353
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.